Merck & Co., Inc., Rahway, N.J., USA DME Drug Meets Phase 2b/3 Non-Inferiority

Merck said remigromig met the primary endpoint of non-inferiority to 0.5 mg ranibizumab in BCVA at 52 weeks in the pivotal Phase 2b/3 BRUNELLO DME trial; higher rates of PDR, vitreous hemorrhage, and AE-related discontinuations were seen vs ranibizumab.Material DetailsContext by AI AnalystThis is a…